Prognostic value of intermediate 18F-FDG PET/CT metabolic parameters combined with intermediate clinical indicators for end-stage efficacy in patients with lymphoma
Objective:To investigate the predictive value of intermediate 18F-FDG PET/CT metabolic parameters combined with intermediate clinical indicators in the end-stage efficacy of lymphoma patients.Methods:Clinical and imaging data of 60 patients with pathologically confirmed lymphoma were retrospectively analyzed,and they were divided into complete response group(CR) and incomplete response group(NCR) according to the evaluation criteria of end-stage Lugano.Comparison of clini-cal features,laboratory indicators and PET parameters was conducted using Mann-Whitney U test,Chi-square test and Fisher test.Multivariate stepwise logistic regression was used to analyze independent risk factors of end-stage NCR group,and logis-tic regression model was established based on the screening results.The diagnostic efficiency was analyzed by ROC curve.The model was tested with external validation data (n=15).Results:Of the 60 patients with lymphoma,23 cases (38.3％) were in CR group and 37 cases (61.7％) in NCR group.There were significant differences in the interim efficacy evaluation(CR/PR),SUVmax,SUVavg,SUVpeak,SULmax,SULavg and SULpeak between the CR group and the NCR group(x2/z=-4.64～14.59,P<0.05).Regression model was established.Interim efficacy evaluation (CR/PR),SULpeak and regression model AUC were(0.836;0.729;0.913,P<0.05),the prediction accuracy of NCR by regression model reached 87.7％,and the accuracy of regression e-quation tested by external validation data was 11/15.Conclusion:Mid-term PET/CT metabolic parameter SULpeak combined with interim efficacy evaluation(CR/PR) has a high predictive value for the end-stage efficacy of lymphoma patients.
万方数据
